Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
Shorter exposure than the DAC conjugate because there is no designed albumin anchor. A half-life number was not extracted.
Forum labels often use CJC-1295 for this shorter analog. The name is not the structure.
Same GHRH-receptor start as the DAC version, without the albumin anchor. The pulse is shorter. IGF-1 may move less because exposure is shorter. A measured comparison was not extracted.
DPP-IV is the peptidase this analog is built to resist. That is a stability pathway, not a dopamine pathway.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
DAC confusion · unverified
Threads argue about DAC, "mod GRF," and CJC as if the names were one SKU. The albumin-binding complex is either present or not. Forum confidence is higher than the labels.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.